Ahmad, P., Estrin, N., Farshidfar, N., Zhang, Y., & Miron, R. J. (2025). Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) improve periodontal and peri‐implant health in type 2 diabetes mellitus. Journal of periodontal research, 60(5), 450-465. https://doi.org/10.1111/jre.13410
Gheonea, T. C., Șurlin, P., Nicolae, F. M., Gheorghe, D. N., Popescu, D. M., & Rogoveanu, I. (2024). Dipeptidyl-Peptidase-4 and glucagon-like-peptide-1, a link in the connection between periodontitis and diabetes mellitus—what do we know so far?—a scoping review. Journal of Clinical Medicine, 13(3), 903. https://doi.org/10.3390/jcm13030903
Mawardi, H. H., Almazrooa, S. A., Dakhil, S. A., Aboalola, A. A., Al-Ghalib, T. A., Eshky, R. T., ... & Mawardi, M. H. (2023). Semaglutide-associated hyposalivation: A report of case series. Medicine, 102(52), e36730. https://doi.org/10.1097/MD.0000000000036730
Fukuda, M. (2021). The role of GIP receptor in the CNS for the pathogenesis of obesity. Diabetes, 70(9), 1929-1937. https://doi.org/10.2337/dbi21-0001
Jensterle, M., Ferjan, S., Battelino, T., Kovač, J., Battelino, S., Šuput, D., ... & Janež, A. (2021). Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial. Trials, 22(1), 464. https://doi.org/10.1186/s13063-021-05442-y
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020). How may GIP enhance the therapeutic efficacy of GLP-1?. Trends in Endocrinology & Metabolism, 31(6), 410-421. https://doi.org/10.1016/j.tem.2020.02.006
Endocrine Society. (2024, June 1). GLP-1 has the power to change taste sensitivity in women with obesity. https://www.endocrine.org/news-and-advocacy/news-room/2024/endo-2024-press-jensterle-sever